Updated on 26 May 2026
TAPR
Marketing Trainee at Psychomeasure
Aveiro, Portugal
About
Class I SaMD platform that functions as a test for the mind, enabling early detection of psychosis risk through objective biomarkers assessment. With over 90% accuracy, it can predict the transition to psychosis up to two years before a clinical outbreak, while remaining completely language-independent.
Type
- Pilot Projects, Testing & Validation
- Business Development & Market Access
- Partnerships & Collaborative Projects
Applies to
- Healthcare & Life Sciences
Similar opportunities
Investment
- Pre-seed & Seed Funding
- Healthcare & Life Sciences
Andreia Pereira
Marketing Trainee at Psychomeasure
Aveiro, Portugal
Service
- Research, Development & Innovation
- Pilot Projects, Testing & Validation
- Partnerships & Collaborative Projects
Henrique Ferreira
Co-founder and CEO HFA Group at HFA,SA
Agueda- Aveiro, Portugal
Project cooperation
Talk to me if you run a field sales team
- Validation & Piloting
- Strategic Partnership
- Investment / Capital Contribution
- Market Access & Commercialisation
- Research & Innovation Collaboration
Guilherme Bento
Founder @OmniMap at OmniMap
Torres Novas, Portugal